

19 May 2025 Australia

**ASX RELEASE****VECTION SIGNS \$1.7m PARTNERSHIP WITH LEARDAL**

Vection Technologies Ltd (ASX:VR1, OTC:VCTNY), ("Vection" or the "Company"), the INTEGRATEDXR<sup>®</sup> company, is pleased to announce it has entered into a three-year partnership with healthcare-simulation specialist Laerdal Italia S.r.l. ("Laerdal") to commercialise Vection's XR and AI portfolio across Italy's healthcare sector and generate \$1.7m in revenue by 30 June 2028.

**HIGHLIGHTS:**

- Agreement with healthcare-training leader Laerdal to generate \$1.7m in sales across three years.
- Laerdal is a global simulation leader with over 2,000 employees in 26 countries and solutions used by hospitals, universities, and first-responder organisations worldwide.
- Vection's XR and AI suite, 3DFrame, EnWorks Remote Assistance and Algho AI, along with Laerdal's conversational coaching will deliver a new, high-performance solution in the healthcare market.
- Success in Italy will open a pathway to a broader European and global rollout, underpinned by joint marketing, demo centres and aligned roadmaps.

**OVERVIEW**

For more than sixty years, Laerdal has empowered clinicians and first responders to practise life-saving techniques using high-fidelity manikins and performance-tracking software. With the integration of Vection's technology, these simulations will transition from static drills to immersive, data-enhanced learning experiences. Learners can explore photorealistic anatomy through 3DFrame, receive real-time remote coaching via EnWorks Remote Assistance, and benefit from Algho AI, which offers conversational guidance while converting each action into measurable insights.

The partnership grants Vection immediate access to Laerdal's established sales channels and strong customer relationships, thereby boosting recurring software revenue and enhancing brand visibility in the healthcare sector. The revenues are distributed across three fiscal period as follows:

\$ 350k on FY26

\$ 600k on FY27

\$ 750k on FY28

Laerdal will integrate advanced interactivity and analytics into its portfolio, enhancing customer value and creating new subscription-based revenue opportunities. Italy is one of Laerdal's key European markets and will act as the launching point; after validating the model, both companies plan to implement it throughout Laerdal's broader European presence and, eventually, its global network.

If the collaboration achieves its commercial objectives, Vection and Laerdal have tentatively agreed to establish a new standard in simulation-based healthcare education by strengthening the integration of AR-and-VR solutions and manikins for even more immersive education. Work under the agreement commences immediately, the agreement can be terminated with 3 months' notice from either party.

Gianmarco Biagi, Managing Director, Vection Technologies, commented: *"Laerdal's standing in clinical education positions it as the perfect avenue for our XR and AI suite. Their dedication to the \$1.7m goal demonstrates genuine belief in 3DFrame, EnWorks, and Algho to enhance training results, initially in Italy and subsequently throughout Europe."*

Novella Callero, CEO, Laerdal Italia, commented: *"By incorporating Vection's immersive and AI-driven tools, we can provide enhanced, data-driven learning experiences that improve patient safety. We are thrilled to lead this innovation in Italy and eventually extend it to Laerdal customers globally."*

**VECTION TECHNOLOGIES LTD**

ASX:VR1; OTC:VCTNY | ACN: 614 814 041

**GLOBAL OFFICES**

PERTH | SYDNEY | SAN FRANCISCO | MILAN | BOLOGNA | ROME | BARI | ABU DHABI | AHMEDABAD

**WEBSITE**

[www.vection-technologies.com](http://www.vection-technologies.com)

**REGISTERED OFFICE**

Level 4, Building C, Garden Office Park, 355  
Scarborough Beach Road,  
Osborne Park WA 6017 - Australia

**MATERIALITY THRESHOLD:**

This announcement is deemed material by the Board as it exceeds the Company's Announcement Materiality Threshold. The Announcement Materiality Threshold is for individual or multiple contracts cumulatively equating to more than \$500k in Revenue.

**AUTHORISATION:**

This ASX release is authorised by the Board of Directors of Vection Technologies Limited.

**ENDS****INVESTOR RELATIONS CONTACT DETAILS:**

Gianmarco Biagi - Managing Director (Europe Based)  
Email: [gianmarco.biagi@vection-technologies.com](mailto:gianmarco.biagi@vection-technologies.com)

Cameron Petricevic - Independent, Non-Executive Director (Australia Based)  
Email: [cameron.petricevic@vection-technologies.com](mailto:cameron.petricevic@vection-technologies.com)

**ABOUT VECTION TECHNOLOGIES:**

Vection Technologies is a growing enterprise-focused company that helps businesses bridge the physical and digital worlds. We help organisations leverage their 3D data via powerful extended reality (XR) interfaces that foster collaboration and learning, grow sales and more.

Vection Technologies is listed on the Australian Securities Exchange (ASX) with ticker code VR1, and trades on the U.S. over-the-counter (OTC) markets under the symbol VCTNY.

For more information, please visit: [www.vection-technologies.com](http://www.vection-technologies.com)

**ABOUT LAERDAL:**

Laerdal Medical, a privately owned Norwegian firm based in Stavanger, specialises in creating simulation manikins, scenario-based software, and data analytics tools for hospitals, universities, emergency response agencies, and defence organisations globally. The company has over 2,000 employees across 26 nations and reports an annual revenue of approximately US \$530 million. Committed to its mission of "helping save one million more lives every year by 2030," Laerdal collaborates with international partners, including the American Heart Association and prominent academic institutions—to enhance patient outcomes through evidence-based, technology-driven training. Laerdal Italia, the company's Italian subsidiary, offers sales, support, and educational services to both public and private healthcare entities across the nation.

For more information, please visit: [www.laerdal.com](http://www.laerdal.com)

**FORWARD-LOOKING STATEMENTS:**

Certain statements made in this release are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Vection Technologies' current expectations, estimates and projections about the industry in which Vection Technologies operates, and beliefs and assumptions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'anticipate', 'believe', 'expect', 'project', 'forecast', 'estimate', 'likely', 'intend', 'should', 'will', 'could', 'may', 'target', 'plan' and other similar expressions within the meaning of securities laws of applicable jurisdictions. Indications of, guidance, or outlook on future earnings, distributions, financial position, or performance are also forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Vection Technologies, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking

**VECTION TECHNOLOGIES LTD**

ASX:VR1; OTC:VCTNY | ACN: 614 814 041

**GLOBAL OFFICES**

PERTH | SYDNEY | SAN FRANCISCO | MILAN | BOLOGNA | ROME | BARI | ABU DHABI | AHMEDABAD

**WEBSITE**

[www.vection-technologies.com](http://www.vection-technologies.com)

**REGISTERED OFFICE**

Level 4, Building C, Garden Office Park, 355  
Scarborough Beach Road,  
Osborne Park WA 6017 - Australia

statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Vection Technologies only as of the date of this release. There can be no assurance that actual outcomes will not differ materially from these forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Vection Technologies has no obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

■ **VECTION TECHNOLOGIES LTD**

ASX:VR1; OTC:VCTNY | ACN: 614 814 041

■ **GLOBAL OFFICES**

■ PERTH | SYDNEY | SAN FRANCISCO | MILAN | BOLOGNA | ROME | BARI | ABU DHABI | AHMEDABAD

■ **WEBSITE**

[www.vection-technologies.com](http://www.vection-technologies.com)

■ **REGISTERED OFFICE**

Level 4, Building C, Garden Office Park, 355  
Scarborough Beach Road,  
Osborne Park WA 6017 - Australia